|Fogarty International Center Awards Research Training Grants
to Tackle AIDS and Tuberculosis
The Fogarty International Center (FIC), part of the National Institutes of
Health (NIH), today announced it funded institutions in Brazil and Zimbabwe,
along with partner institutions in the United States, to establish research training
programs to improve in-country capacity to fight AIDS and TB.
The awards were made through FICís International Clinical, Operational, and
Health Services Research Training Award Program for AIDS and Tuberculosis (ICOHRTA-AIDS/TB).
One group of partner awardees includes Dr. Jose R. Lapa e Silva of the Federal
University of Rio de Janeiro (Rio de Janeiro, Brazil) and Dr. Richard Chaisson
of Johns Hopkins University (Baltimore, MD). They will establish a research training
program at the Federal University of Rio de Janeiro to develop a new cadre of
clinical and health service researchers who will contribute toward controlling
TB and TB-HIV co-infection in Brazil.
The other group includes Dr. Peter Mason of the Biomedical Research and Training
Institute (Harare, Zimbabwe) and Dr. David Katzenstein of Stanford University
in (Stanford, CA). They will establish a research training program in Zimbabwe
to strengthen the capacity of African scientists to design, develop and conduct
effective, relevant and ethical research studies, focusing on HIV, TB and other
The ICOHRTA-AIDS/TB program supports research training to strengthen skills
needed to design and conduct AIDS and TB research for the scale-up of promising
interventions to the population and health care system levels. This new funding
brings the total of awards to 12 and includes eight that were initially made
in 2004 for sites in China, Haiti, Russia and Uganda. FIC will add $6 million
for these awards to the previous total of $12 million made by FIC and its NIH
partners and the United States Agency for International Development (USAID).
"As treatment drugs become more available, a pressing need will be to monitor
and evaluate their effectiveness in the population. This program supports the
research training to meet that need," said Sharon Hrynkow, Ph.D., FIC Acting
Director, speaking on behalf of the program sponsors.
FIC developed ICOHRTA-AIDS/TB in collaboration with NIH's National Institute
of Allergy and Infectious Diseases, National Institute on Alcohol Abuse and Alcoholism,
National Cancer Institute, National Institute of Child Health and Human Development,
National Institute on Drug Abuse, National Institute of Mental Health, National
Institute of Neurological Disorders and Stroke, Office of AIDS Research, and
Office of Research on Women's Health, Centers for Disease Control and Prevention,
"These additional research training programs in Brazil and Zimbabwe will strengthen
the in-country capacity so that large-scale prevention, treatment and care interventions
are locally relevant and effective," noted Jeanne McDermott, CNM, MPH, PhD, Program
Officer for FIC ICOHRTA AIDS/TB.
More information about the ICOHRTA AIDS/TB program can be found at this URL: http://www.fic.nih.gov/programs/ICOHRTA-AIDS-TB/ICOHRTA-AIDS-TB.html.
FIC, the international component of the NIH, addresses global health challenges
through innovative and collaborative research and training programs and supports
and advances the NIH mission through international partnerships.
The National Institutes of Health (NIH) — The Nation's Medical Research
Agency — includes 27 Institutes and Centers and is a component of
the U. S. Department of Health and Human Services. It is the primary Federal
agency for conducting and supporting basic, clinical, and translational medical
research, and it investigates the causes, treatments, and cures for both common
and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.